Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma

Federica Ermetici, Alexis E. Malavazos, Sabrina Corbetta, Lelio Morricone, Chiara Dall'Asta, Massimiliano M. Corsi, Bruno Ambrosi

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors, similar to overt Cushing syndrome. Data about the involvement of the adipokines in the development of insulin resistance and atherosclerosis in AI are completely lacking. The aim of the present study was to evaluate plasma interleukin 6 (IL-6), adiponectin, resistin, tumor necrosis factor α (TNF-α), and monocyte chemoattractant protein 1 (MCP-1) levels in patients with AI. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were measured in 20 healthy subjects (6 males; 14 females; age, 58.5 ± 2.2 years; body mass index, 28.1 ± 0.9 kg/m2) and in 20 patients (5 males; 15 females; age, 57.9 ± 2.0 years; body mass index, 28.0 ± 0.8 kg/m2) with AI and typical computed tomographic features of cortical adenoma, who were not affected by diabetes mellitus, hypertension, or other relevant diseases. All patients underwent anthropometric measurements and determination of basal corticotropin, cortisol, and urinary free cortisol excretion. Overnight dexamethasone test and 250-μg corticotropin test were performed in all cases. A subclinical Cushing syndrome was found in 3 patients, whereas the others had apparently nonfunctioning masses. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were higher in patients than in controls (64.4 ± 2.8 vs 5.5 ± 0.6 pg/mL, 13.7 ± 1.3 vs 3.6 ± 0.5 μg/mL, 12.5 ± 1.9 vs 5.1 ± 0.2 ng/mL, 27.0 ± 1.5 vs 22.2 ± 1.5 pg/mL, 172.5 ± 20.0 vs 104.4 ± 19.5 pg/mL, respectively; P <.05) and apparently not affected by the presence of visceral obesity. Plasma IL-6 levels were negatively correlated with urinary free cortisol (r = -0.461, P <.05), and TNF-α levels were positively correlated with cortisol after the administration of 1 mg dexamethasone (r = 0.636, P <.01). In conclusion, patients with AI may show increased levels of adipokines (apparently not related to the presence of diabetes, hypertension, or obesity), which may be affected by the presence of the adrenal adenoma. For some adipokines, a direct production from the adrenal gland may be hypothesized even if other studies are needed to better investigate the role of adipokines in states of altered cortisol secretion.

Original languageEnglish
Pages (from-to)686-692
Number of pages7
JournalMetabolism
Volume56
Issue number5
DOIs
Publication statusPublished - May 2007

Fingerprint

Adipokines
Hydrocortisone
Resistin
Chemokine CCL2
Interleukin-6
Adiponectin
Tumor Necrosis Factor-alpha
Cushing Syndrome
Adenoma
Adrenocorticotropic Hormone
Dexamethasone
Body Mass Index
Hypertension
Abdominal Obesity
Adrenal Glands
Insulin Resistance
Adrenal incidentaloma
Atherosclerosis
Diabetes Mellitus
Healthy Volunteers

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. / Ermetici, Federica; Malavazos, Alexis E.; Corbetta, Sabrina; Morricone, Lelio; Dall'Asta, Chiara; Corsi, Massimiliano M.; Ambrosi, Bruno.

In: Metabolism, Vol. 56, No. 5, 05.2007, p. 686-692.

Research output: Contribution to journalArticle

Ermetici, Federica ; Malavazos, Alexis E. ; Corbetta, Sabrina ; Morricone, Lelio ; Dall'Asta, Chiara ; Corsi, Massimiliano M. ; Ambrosi, Bruno. / Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. In: Metabolism. 2007 ; Vol. 56, No. 5. pp. 686-692.
@article{1cab0ef7859044e6986cd7defde1d2c4,
title = "Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma",
abstract = "Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors, similar to overt Cushing syndrome. Data about the involvement of the adipokines in the development of insulin resistance and atherosclerosis in AI are completely lacking. The aim of the present study was to evaluate plasma interleukin 6 (IL-6), adiponectin, resistin, tumor necrosis factor α (TNF-α), and monocyte chemoattractant protein 1 (MCP-1) levels in patients with AI. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were measured in 20 healthy subjects (6 males; 14 females; age, 58.5 ± 2.2 years; body mass index, 28.1 ± 0.9 kg/m2) and in 20 patients (5 males; 15 females; age, 57.9 ± 2.0 years; body mass index, 28.0 ± 0.8 kg/m2) with AI and typical computed tomographic features of cortical adenoma, who were not affected by diabetes mellitus, hypertension, or other relevant diseases. All patients underwent anthropometric measurements and determination of basal corticotropin, cortisol, and urinary free cortisol excretion. Overnight dexamethasone test and 250-μg corticotropin test were performed in all cases. A subclinical Cushing syndrome was found in 3 patients, whereas the others had apparently nonfunctioning masses. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were higher in patients than in controls (64.4 ± 2.8 vs 5.5 ± 0.6 pg/mL, 13.7 ± 1.3 vs 3.6 ± 0.5 μg/mL, 12.5 ± 1.9 vs 5.1 ± 0.2 ng/mL, 27.0 ± 1.5 vs 22.2 ± 1.5 pg/mL, 172.5 ± 20.0 vs 104.4 ± 19.5 pg/mL, respectively; P <.05) and apparently not affected by the presence of visceral obesity. Plasma IL-6 levels were negatively correlated with urinary free cortisol (r = -0.461, P <.05), and TNF-α levels were positively correlated with cortisol after the administration of 1 mg dexamethasone (r = 0.636, P <.01). In conclusion, patients with AI may show increased levels of adipokines (apparently not related to the presence of diabetes, hypertension, or obesity), which may be affected by the presence of the adrenal adenoma. For some adipokines, a direct production from the adrenal gland may be hypothesized even if other studies are needed to better investigate the role of adipokines in states of altered cortisol secretion.",
author = "Federica Ermetici and Malavazos, {Alexis E.} and Sabrina Corbetta and Lelio Morricone and Chiara Dall'Asta and Corsi, {Massimiliano M.} and Bruno Ambrosi",
year = "2007",
month = "5",
doi = "10.1016/j.metabol.2006.12.018",
language = "English",
volume = "56",
pages = "686--692",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma

AU - Ermetici, Federica

AU - Malavazos, Alexis E.

AU - Corbetta, Sabrina

AU - Morricone, Lelio

AU - Dall'Asta, Chiara

AU - Corsi, Massimiliano M.

AU - Ambrosi, Bruno

PY - 2007/5

Y1 - 2007/5

N2 - Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors, similar to overt Cushing syndrome. Data about the involvement of the adipokines in the development of insulin resistance and atherosclerosis in AI are completely lacking. The aim of the present study was to evaluate plasma interleukin 6 (IL-6), adiponectin, resistin, tumor necrosis factor α (TNF-α), and monocyte chemoattractant protein 1 (MCP-1) levels in patients with AI. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were measured in 20 healthy subjects (6 males; 14 females; age, 58.5 ± 2.2 years; body mass index, 28.1 ± 0.9 kg/m2) and in 20 patients (5 males; 15 females; age, 57.9 ± 2.0 years; body mass index, 28.0 ± 0.8 kg/m2) with AI and typical computed tomographic features of cortical adenoma, who were not affected by diabetes mellitus, hypertension, or other relevant diseases. All patients underwent anthropometric measurements and determination of basal corticotropin, cortisol, and urinary free cortisol excretion. Overnight dexamethasone test and 250-μg corticotropin test were performed in all cases. A subclinical Cushing syndrome was found in 3 patients, whereas the others had apparently nonfunctioning masses. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were higher in patients than in controls (64.4 ± 2.8 vs 5.5 ± 0.6 pg/mL, 13.7 ± 1.3 vs 3.6 ± 0.5 μg/mL, 12.5 ± 1.9 vs 5.1 ± 0.2 ng/mL, 27.0 ± 1.5 vs 22.2 ± 1.5 pg/mL, 172.5 ± 20.0 vs 104.4 ± 19.5 pg/mL, respectively; P <.05) and apparently not affected by the presence of visceral obesity. Plasma IL-6 levels were negatively correlated with urinary free cortisol (r = -0.461, P <.05), and TNF-α levels were positively correlated with cortisol after the administration of 1 mg dexamethasone (r = 0.636, P <.01). In conclusion, patients with AI may show increased levels of adipokines (apparently not related to the presence of diabetes, hypertension, or obesity), which may be affected by the presence of the adrenal adenoma. For some adipokines, a direct production from the adrenal gland may be hypothesized even if other studies are needed to better investigate the role of adipokines in states of altered cortisol secretion.

AB - Adrenal incidentalomas (AIs) have been associated with an increased incidence of several cardiovascular risk factors, similar to overt Cushing syndrome. Data about the involvement of the adipokines in the development of insulin resistance and atherosclerosis in AI are completely lacking. The aim of the present study was to evaluate plasma interleukin 6 (IL-6), adiponectin, resistin, tumor necrosis factor α (TNF-α), and monocyte chemoattractant protein 1 (MCP-1) levels in patients with AI. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were measured in 20 healthy subjects (6 males; 14 females; age, 58.5 ± 2.2 years; body mass index, 28.1 ± 0.9 kg/m2) and in 20 patients (5 males; 15 females; age, 57.9 ± 2.0 years; body mass index, 28.0 ± 0.8 kg/m2) with AI and typical computed tomographic features of cortical adenoma, who were not affected by diabetes mellitus, hypertension, or other relevant diseases. All patients underwent anthropometric measurements and determination of basal corticotropin, cortisol, and urinary free cortisol excretion. Overnight dexamethasone test and 250-μg corticotropin test were performed in all cases. A subclinical Cushing syndrome was found in 3 patients, whereas the others had apparently nonfunctioning masses. Plasma IL-6, adiponectin, resistin, TNF-α, and MCP-1 levels were higher in patients than in controls (64.4 ± 2.8 vs 5.5 ± 0.6 pg/mL, 13.7 ± 1.3 vs 3.6 ± 0.5 μg/mL, 12.5 ± 1.9 vs 5.1 ± 0.2 ng/mL, 27.0 ± 1.5 vs 22.2 ± 1.5 pg/mL, 172.5 ± 20.0 vs 104.4 ± 19.5 pg/mL, respectively; P <.05) and apparently not affected by the presence of visceral obesity. Plasma IL-6 levels were negatively correlated with urinary free cortisol (r = -0.461, P <.05), and TNF-α levels were positively correlated with cortisol after the administration of 1 mg dexamethasone (r = 0.636, P <.01). In conclusion, patients with AI may show increased levels of adipokines (apparently not related to the presence of diabetes, hypertension, or obesity), which may be affected by the presence of the adrenal adenoma. For some adipokines, a direct production from the adrenal gland may be hypothesized even if other studies are needed to better investigate the role of adipokines in states of altered cortisol secretion.

UR - http://www.scopus.com/inward/record.url?scp=34147159267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147159267&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2006.12.018

DO - 10.1016/j.metabol.2006.12.018

M3 - Article

C2 - 17445545

AN - SCOPUS:34147159267

VL - 56

SP - 686

EP - 692

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 5

ER -